CAMBRIDGE, Mass., March 7, 2019 /PRNewswire/ --áInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference callon Thursday, March 14, 2019, at 8:00 a.m. ET to review its full year 2018 financial results and provide an update on the company.
A live webcast of the conference call can be accessed
About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 225 patients with advanced solid tumors is ongoing and Infinity intends to initiate MARIO-275, a combination study of IPI-549 with Opdivo«áin I/O na´ve urothelial cancer (UC) patients, as well as initiate the first IPI-549 combination study in front-line advanced cancer patients, in 2019. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:Stephanie Ascher, Stern Investor Relations, Inc.212-362-1200 or Stephanie@sternir.com
View original content:http://www.prnewswire.com/news-releases/infinity-announces-the-date-of-its-full-year-2018-financial-results-conference-call-and-webcast-300808760.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!